Fertsy will unveil its latest research results at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE 2025). Together with the American Society for Reproductive Medicine (ASRM) Annual Meeting that Fertsy attended late last year, ESHRE is regarded as one of the world’s two leading reproductive medicine conferences. The exhibition and scientific sessions will be held from June 29 to July 2, 2025, at the Paris Expo Porte de Versailles in Paris, France. At the exhibition, Fertsy will fully showcase a range of AI-based solutions for fertility centers at Booth A011.
Meanwhile, following review by the conference scientific committee, a research abstract titled “Generalization validation of an interpretable artificial intelligence embryo selection model: a Cross-Brand retrospective study,” co-authored by Fertsy and the Reproductive Medicine Center of Nanjing Drum Tower Hospital, has been accepted for presentation (Abstract No. P-095). This retrospective internal-external validation study confirms the consistency of embryo selection performance of Fertsy’s AI embryo assessment system, EmbryoInsights, across different brands of time-lapse imaging systems (Astec CCM-iBIS vs. Vitrolife EmbryoScope). The results show no significant difference in predictive performance between the two datasets. The study demonstrates that EmbryoInsights, as an interpretable AI system, can effectively adapt to differences in hardware and software across different clinical centers, providing consistent assessment outcomes.
At the concurrent ESHRE 2025 exhibition, Fertsy showcased the latest advancements in EmbryoInsights™, its AI-powered embryo assessment tool, and CryoTrio™, the intelligent liquid nitrogen storage monitoring system. The booth warmly welcomed visitors from around the world, generating more than seventy client leads.
